ZGN-1061 is an experimental drug that was developed by
Zafgen for treatment of obesity and type 2 diabetes. It has a similar mechanism of action as the discontinued drug
Beloranib but was considered safer; however, its development was also halted because of safety concerns.[1][2][3]
^Wentworth, John M.; Colman, Peter G. (July 2020). "The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placebo-controlled trial". Diabetes, Obesity and Metabolism. 22 (7): 1215–1219.
doi:
10.1111/dom.14009.
hdl:11343/275507.
PMID32077231.
^Goya Grocin, Andrea; Kallemeijn, Wouter W.; Tate, Edward W. (October 2021). "Targeting methionine aminopeptidase 2 in cancer, obesity, and autoimmunity". Trends in Pharmacological Sciences. 42 (10): 870–882.
doi:
10.1016/j.tips.2021.07.004.
hdl:10044/1/102175.
PMID34446297.